Page 16 - சிஇஎன்டியுவ்ஆர்ஒய் குணப்படுத்துகிறது News Today : Breaking News, Live Updates & Top Stories | Vimarsana

By Stephen Northrup Dec. 21, 2020Reprints The investigation by Sen. Michael Enzi (R-Wyo.) into the approval and subsequent withdrawal of Vioxx led to sweeping changes in ensuring drug safety. Samuel Corum/Getty Images The prescription painkiller originally known as Vioxx may be making a comeback after its maker, Merck, abruptly pulled it from the market in 2004 following studies that showed the drug roughly doubled patients’ risks of heart attack and stroke and may have contributed to an estimated 60,000 deaths. According to STAT, Tremeau Pharmaceuticals, a privately held Massachusetts drug company, is about to begin clinical trials of rofecoxib (the generic name for Vioxx) as a treatment for hemophilic arthropathy, a persistent joint disease for which doctors often prescribed Vioxx off-label.

United statesMichael enziBrookings institutionInstitute of medicineTremeau pharmaceuticalsSenate committee on healthDrug administrationNational academy of medicineCapitol hillEdward kennedyNew england journalSenate committeeEnsuring drug safetyInnovation actNational academyPrescription drug user fee act